Shanghai Henlius Biotech IPO: Cash Breakeven Analysis
Shanghai Henlius Biotech (1566213D HK) is a biopharmaceutical company and a non-wholly owned subsidiary of Shanghai Fosun Pharmaceutical (Group)...
412 Views
Shanghai Henlius (复宏汉霖) IPO: Thoughts on Valuation
Shanghai Henlius, a subsidiary of Fosun Pharma, is seeking to list in Hong Kong. In our previous insights covering Shanghai Henlius, we have...
561 Views
Shanghai Henlius Biotech IPO Initiation: Going Large
Shanghai Henlius Biotech (1566213D HK) is a biopharmaceutical company and a non-wholly owned subsidiary of Shanghai Fosun Pharmaceutical (Group)...
643 Views
Shanghai Henlius (复宏汉霖) IPO: What's New in the Re-Filed Prospectus?
Shanghai Henlius, a subsidiary of Fosun Pharma, is seeking to list in Hong Kong. Shortly after its previous application lapsed, the company refiled...
680 Views
ECM Weekly (6 Jul 2019) - Budweiser APAC, Prime US REIT, Topsports, Douyu, JS Global, China Feihe
Aequitas Research puts out a weekly update on the deals that have been covered by Smartkarma Insight Providers recently, along with updates for...
522 Views